Payment overview · 2025
General Payments
$48.60
3 reported records · 3 companies
Healthcare provider profile · identity verified
Shannon Coleman
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PENSACOLA, FL · NPI 1326504374
Verified facts
What the public records show
CMS Open Payments records show Shannon Coleman received $48.60 in general payments during 2025 across 3 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 48.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.75 | 48.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.72 | 38.5% | 1 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $6.13 | 12.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $48.60 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $6.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 570 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 308 | 47 |
| Eliquis | Apixaban | 298 | 33 |
| Gabapentin | Gabapentin | 231 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 189 | 33 |
| Furosemide | Furosemide | 160 | 37 |
| Lisinopril | Lisinopril | 154 | 22 |
| Potassium Chloride | Potassium Chloride | 152 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 30 |
| Divalproex Sodium | Divalproex Sodium | 133 | 22 |
| Trazodone Hcl | Trazodone Hcl | 132 | 23 |
| Levetiracetam | Levetiracetam | 131 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 130 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 22 |
| Metformin Hcl | Metformin Hcl | 127 | 20 |
| Sertraline Hcl | Sertraline Hcl | 113 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 112 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 19 |
| Losartan Potassium | Losartan Potassium | 100 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 11 |
| Mirtazapine | Mirtazapine | 93 | 21 |
| Trulicity | Dulaglutide | 93 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 90 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 17 |
| Montelukast Sodium | Montelukast Sodium | 87 | 16 |
| Carvedilol | Carvedilol | 73 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 11 |
| Jardiance | Empagliflozin | 72 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 55 | 13 |
| Olanzapine | Olanzapine | 54 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | 14 |
| Donepezil Hcl | Donepezil Hcl | 51 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 50 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 50 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 30 |
| Metformin Hcl Er | Metformin Hcl | 48 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 28 |
| Novolog Flexpen | Insulin Aspart | 45 | suppressed |
| Omeprazole | Omeprazole | 43 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | suppressed |
| Lorazepam | Lorazepam | 40 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 24 |
| Sucralfate | Sucralfate | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 36 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | 20 |
| Linzess | Linaclotide | 34 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 13 |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 31 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 27 | 17 |
| Cephalexin | Cephalexin | 27 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 14 |
| Allopurinol | Allopurinol | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | 11 |
| Prednisone | Prednisone | 26 | 16 |
| Spironolactone | Spironolactone | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Clozapine | Clozapine | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 11 |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | 16 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Olanzapine Odt | Olanzapine | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Erythromycin | Erythromycin Base | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 18 | 13 |
| Lokelma | Sodium Zirconium Cyclosilicate | 18 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Baclofen | Baclofen | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Propylthiouracil | Propylthiouracil | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $48.60 · 3 records | Otsuka America Pharmaceutical, Inc. | AUSTEDO XR, REXULTI, Zunveyl | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error